Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 552

1.

Socially-assigned race and health: a scoping review with global implications for population health equity.

White K, Lawrence JA, Tchangalova N, Huang SJ, Cummings JL.

Int J Equity Health. 2020 Feb 10;19(1):25. doi: 10.1186/s12939-020-1137-5. Review.

2.

Unique white matter structural connectivity in early-stage, drug-naive Parkinson disease.

Mishra VR, Sreenivasan KR, Yang Z, Zhuang X, Cordes D, Mari Z, Litvan I, Fernandez HH, Eidelberg D, Ritter A, Cummings JL, Walsh RR.

Neurology. 2019 Dec 27. pii: 10.1212/WNL.0000000000008867. doi: 10.1212/WNL.0000000000008867. [Epub ahead of print]

PMID:
31882528
3.

Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume.

Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O.

Alzheimers Res Ther. 2019 Dec 26;11(1):109. doi: 10.1186/s13195-019-0565-1.

4.

Effect of dietary cellulose supplementation on gut barrier function and apoptosis in a murine model of endotoxemia.

Di Caro V, Alcamo AM, Cummings JL, Clark RSB, Novak EA, Mollen KP, Morowitz MJ, Aneja RK.

PLoS One. 2019 Dec 2;14(12):e0224838. doi: 10.1371/journal.pone.0224838. eCollection 2019.

5.

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.

Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade RD, Cummings JL.

Am J Geriatr Psychiatry. 2019 Oct 1. pii: S1064-7481(19)30521-4. doi: 10.1016/j.jagp.2019.09.009. [Epub ahead of print]

6.

Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.

Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG.

Am Heart J. 2019 Nov;217:72-83. doi: 10.1016/j.ahj.2019.08.001. Epub 2019 Aug 9.

PMID:
31520897
7.

Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults.

Brunet HE, Cummings JL, Banks SJ, Miller JB.

J Geriatr Psychiatry Neurol. 2019 Aug 11:891988719868311. doi: 10.1177/0891988719868311. [Epub ahead of print]

PMID:
31401920
8.

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D.

Alzheimers Res Ther. 2019 Aug 7;11(1):68. doi: 10.1186/s13195-019-0520-1.

9.

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease.

Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, Tariot PN, Raket LL.

Alzheimers Dement (N Y). 2019 May 20;5:164-174. doi: 10.1016/j.trci.2019.04.001. eCollection 2019.

10.

Emotional and physical reactions to perceived discrimination, language preference, and health-related quality of life among Latinos and Whites.

White K, Lawrence JA, Cummings JL, Fisk C.

Qual Life Res. 2019 Oct;28(10):2799-2811. doi: 10.1007/s11136-019-02222-9. Epub 2019 Jun 10.

PMID:
31183603
11.

Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease.

Bayram E, Shan G, Cummings JL.

J Alzheimers Dis. 2019;69(4):953-961. doi: 10.3233/JAD-181285.

12.

Socially Assigned Race and Diabetes: Findings from the Arizona Behavioral Risk Factor Surveillance System, 2013-2014.

Lawrence JA, White K, Cummings JL, Hardin JW, Torres ME.

J Racial Ethn Health Disparities. 2019 Oct;6(5):926-934. doi: 10.1007/s40615-019-00593-w. Epub 2019 May 7.

PMID:
31065999
13.

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.

PMID:
30970186
14.

Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.

Cummings JL, Tong G, Ballard C.

J Alzheimers Dis. 2019;67(3):779-794. doi: 10.3233/JAD-180766. Review.

15.

Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease.

Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Geist MA, Raket LL, Cummings JL.

J Alzheimers Dis. 2019;67(1):303-313. doi: 10.3233/JAD-180595.

PMID:
30636738
16.

Unsuccessful trials of therapies for Alzheimer's disease.

Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC.

Lancet. 2019 Jan 5;393(10166):29. doi: 10.1016/S0140-6736(18)31896-8. No abstract available.

PMID:
30614456
17.

Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program.

Cummings JL, Atri A, Ballard C, Boneva N, Frölich L, Molinuevo JL, Raket LL, Tariot PN.

Alzheimers Res Ther. 2018 Nov 24;10(1):116. doi: 10.1186/s13195-018-0443-2.

18.

Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer's Disease.

Banks SJ, Zhuang X, Bayram E, Bird C, Cordes D, Caldwell JZK, Cummings JL; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;66(3):1223-1234. doi: 10.3233/JAD-180541.

19.

Genetic Risk of Alzheimer's Disease: Three Wishes Now That the Genie is Out of the Bottle.

Frank L, Wesson Ashford J, Bayley PJ, Borson S, Buschke H, Cohen D, Cummings JL, Davies P, Dean M, Finkel SI, Hyer L, Perry G, Powers RE, Schmitt F.

J Alzheimers Dis. 2018;66(2):421-423. doi: 10.3233/JAD-180629.

20.

Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson's disease.

Cordes D, Zhuang X, Kaleem M, Sreenivasan K, Yang Z, Mishra V, Banks SJ, Bluett B, Cummings JL.

Alzheimers Dement (N Y). 2018 Jun 14;4:372-386. doi: 10.1016/j.trci.2018.04.009. eCollection 2018.

21.

Statistical advances in clinical trials and clinical research.

Shan G, Banks S, Miller JB, Ritter A, Bernick C, Lombardo J, Cummings JL.

Alzheimers Dement (N Y). 2018 Jun 14;4:366-371. doi: 10.1016/j.trci.2018.04.006. eCollection 2018.

22.

Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods.

Cummings JL, Fulkerson N.

Alzheimers Dement (N Y). 2018 Jun 1;4:326-329. doi: 10.1016/j.trci.2018.03.008. eCollection 2018. No abstract available.

23.

Dietary Cellulose Supplementation Modulates the Immune Response in a Murine Endotoxemia Model.

Di Caro V, Cummings JL, Alcamo AM, Piganelli JD, Clark RSB, Morowitz MJ, Aneja RK.

Shock. 2019 Apr;51(4):526-534. doi: 10.1097/SHK.0000000000001180.

PMID:
30080745
24.

Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study.

Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, Ossinalde C, Silverman DH.

Exp Gerontol. 2018 Oct 1;111:118-121. doi: 10.1016/j.exger.2018.07.009. Epub 2018 Jul 10.

PMID:
30006299
25.

Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume.

Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;64(1):79-89. doi: 10.3233/JAD-180028.

26.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

27.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

28.

Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study.

Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB.

J Alzheimers Dis. 2018;62(1):93-97. doi: 10.3233/JAD-170896.

29.

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.

Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL.

JAMA. 2018 Jan 9;319(2):130-142. doi: 10.1001/jama.2017.20373.

30.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13.

31.

Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease.

Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Riordan H, Scheinin M, Soininen H, Rouru J.

Alzheimers Dement (N Y). 2016 Dec 8;3(1):1-9. doi: 10.1016/j.trci.2016.11.004. eCollection 2017 Jan.

32.

Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.

Caldwell JZK, Berg JL, Cummings JL, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2017 Sep 12;9(1):72. doi: 10.1186/s13195-017-0300-8.

33.

Contrasting roles of the ABCG2 Q141K variant in prostate cancer.

Sobek KM, Cummings JL, Bacich DJ, O'Keefe DS.

Exp Cell Res. 2017 May 1;354(1):40-47. doi: 10.1016/j.yexcr.2017.03.020. Epub 2017 Mar 11.

34.

Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory.

Kim HJ, Choi KH, Kim SH, Cummings JL, Yang DW.

Dement Geriatr Cogn Dis Extra. 2016 Jun 3;6(2):214-21. doi: 10.1159/000445828. eCollection 2016 May-Aug.

35.

Concordance of the Montreal cognitive assessment with standard neuropsychological measures.

Vogel SJ, Banks SJ, Cummings JL, Miller JB.

Alzheimers Dement (Amst). 2015 Jun 28;1(3):289-94. doi: 10.1016/j.dadm.2015.05.002. eCollection 2015 Sep.

36.

Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply.

Cummings JL, Siffert J.

JAMA. 2016 Mar 15;315(11):1166-7. doi: 10.1001/jama.2015.18289. No abstract available. Erratum in: JAMA. 2016 Apr 19;315(15):1661.

PMID:
26978215
37.

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J.

Alzheimers Res Ther. 2016 Jan 29;8:4. doi: 10.1186/s13195-016-0173-2.

38.

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J.

JAMA. 2015 Sep 22-29;314(12):1242-54. doi: 10.1001/jama.2015.10214.

PMID:
26393847
39.

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL.

Alzheimers Res Ther. 2015 Jun 25;7(1):39. doi: 10.1186/s13195-015-0122-5. eCollection 2015.

40.

Incidence of dementia and subtypes: A cohort study in four regions in China.

Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q, Tang M, Wu J, Xu Q, Li H, Cummings JL.

Alzheimers Dement. 2016 Mar;12(3):262-71. doi: 10.1016/j.jalz.2015.02.011. Epub 2015 Jun 15.

PMID:
26086181
41.

Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia.

Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ.

J Am Geriatr Soc. 2015 Jul;63(7):1448-52. doi: 10.1111/jgs.13473. Epub 2015 Jun 5.

PMID:
26046666
42.

A practical algorithm for managing Alzheimer's disease: what, when, and why?

Cummings JL, Isaacson RS, Schmitt FA, Velting DM.

Ann Clin Transl Neurol. 2015 Mar;2(3):307-23. doi: 10.1002/acn3.166. Epub 2015 Jan 23. Review.

43.

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.

Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T, Strohmaier C.

Alzheimers Res Ther. 2015 Mar 8;7(1):9. doi: 10.1186/s13195-014-0088-8. eCollection 2015.

44.

Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, Salloway S, Schofield PR, Cummings JL, Buckles V, Bateman R, Morris JC; Dominantly Inherited Alzheimer Network.

Brain. 2015 Apr;138(Pt 4):1036-45. doi: 10.1093/brain/awv004. Epub 2015 Feb 15. Erratum in: Brain. 2015 Dec;138(Pt 12):e401.

45.

Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.

Alva G, Cummings JL, Galvin JE, Meng X, Velting DM.

Int J Clin Pract. 2015 May;69(5):518-30. doi: 10.1111/ijcp.12621. Epub 2015 Feb 16.

PMID:
25684069
46.

Alzheimer's disease.

Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL.

Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56. Review.

PMID:
27188934
47.

Overcoming obstacles to repurposing for neurodegenerative disease.

Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM.

Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.

48.

Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

Cummings JL, Morstorf T, Zhong K.

Alzheimers Res Ther. 2014 Jul 3;6(4):37. doi: 10.1186/alzrt269. eCollection 2014.

49.

Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment.

Cummings JL, Tribanek M, Hoerr R.

Int Psychogeriatr. 2014 Nov;26(11):1871-4. doi: 10.1017/S1041610214001185. Epub 2014 Jul 3.

PMID:
24990088
50.

Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes.

Miller JB, Banks SJ, Léger GC, Cummings JL.

Transl Neurodegener. 2014 Jun 5;3:12. doi: 10.1186/2047-9158-3-12. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center